Disruption of differentiation in human cancer: AML shows the way
The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Abstract
Although much is understood about the ways in which transcription factors regulate various differentiation systems, and one of the hallmarks of many human cancers is a lack of cellular differentiation, relatively few reports have linked these two processes. Recent studies of acute myeloid leukaemia (AML), however, have indicated how disruption of transcription-factor function can disrupt normal cellular differentiation and lead to cancer. This model involves lineage-specific transcription factors, which are involved in normal haematopoietic differentiation. These factors are often targeted in AML--either by direct mutation or by interference from translocation proteins. Uncovering these underlying pathways will improve the diagnosis and treatment of AML, and provide a working model for other types of human cancer, including solid tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Autoregulation may be a common feature of several transcriptional regulators to augment the relatively irreversible nature of differentiation processes in the hematopoietic system (60,61).”
From Potential Autoregulation of Transcription Factor PU.1 by an Upstream Regulatory Element (2005) · cites this paper as [60]
Citations
Cites
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864 · cited 1×
“What is the role of lineage-specific transcription factors on stem cells, and how does this relate to AML? Although most of the blast cells from patients with AML clearly show a lineage- and stage-specific differentiation block, several studies support the idea that it is a disease that also involves the stem-cell com…”
BackgroundBennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Purification and Characterization of Mouse Hematopoietic Stem Cells
Spangrude, G. J., Heimfeld, S., & Weissman, I. L. (1988) · Science · doi:10.1126/science.2898810 · Cited by 2,824
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617
In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Schwarze, S. R., Ho, A., Vocero-Akbani, A., & Dowdy, S. F. (1999) · Science · doi:10.1126/science.285.5433.1569 · Cited by 2,416
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 1×
“This could be applied either in treating bone marrow ex vivo with differentiation agents, followed by bone-marrow transplantation for re-introduction into the patient, or by local therapies, such as instillation into the lung by bronchoscop”
MethodOkuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856 · cited 1×
“Whereas AML1 falls into the category of transcription factors that are involved in the development of haematopoietic cells from haemangioblasts (SCL is another), and disruption of AML1 results in loss of all definitive haematopoiesi”
Background
Research works printed but not linked: 2
- Zhang, P. et al. C/EBPα deficiency blocks granulocytic differentiation at the common myeloid progenitor stage in both adult and fetal liver myelopoiesis. Blood 98, 792a (2001).
- Duprez, E. A., Koch, H. & Tenen, D. G. C/EBPβ is an important target of PML–RARA during ATRA induced differentiation of APL cells. Blood 98, 833a (2001).
Cited by
Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis
Levine, J. H., Simonds, E. F., Bendall, S. C., Davis, K. L., Amir, E.-A. D., Tadmor, M. D., Litvin, O., Fienberg, H. G., Jager, A., Zunder, E. R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.047 · Cited by 2,303
“Arising from the disruption of regulated myeloid differentiation (Tenen, 2003), AML results in a disordered developmental hierarchy wherein leukemic stem cells (LSCs) are capable of re-establishing the disease in immunodeficient mice (Bonnet and Dick, 1997).”
InfluentialStem cell gene expression programs influence clinical outcome in human leukemia
Eppert, K., Takenaka, K., Lechman, E. R., Waldron, L., Nilsson, B., van Galen, P., Metzeler, K. H., Poeppl, A., Ling, V., Beyene, J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2415 · Cited by 1,041
“In AML, stem cell regulation and differentiation are abnormal; self-renewal is much greater in LSCs than in HSCs, and differentiation is deregulated and highly variable among genetic and morphological subtype”
BackgroundHematopoiesis: a human perspective
Doulatov, S., Notta, F., Laurenti, E., & Dick, J. E. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.01.006 · Cited by 895
“A detailed description of these and other molecular pathways implicated in hematological disorders is the subject of a number of excellent reviews (Tenen, 2003).”
BackgroundFazi, F., Rosa, A., Fatica, A., Gelmetti, V., De Marchis, M. L., Nervi, C., & Bozzoni, I. (2005) · Cell · doi:10.1016/j.cell.2005.09.023 · Cited by 894
Passegué, E., Jamieson, C. H. M., Ailles, L. E., & Weissman, I. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2034201100 · Cited by 686
Origins of chromosome translocations in childhood leukaemia
Greaves, M. F., & Wiemels, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1164 · Cited by 699
“These same genes are crucial for the normal function of haematopoietic stem cells, as shown by knockout experiments in mic”
BackgroundCancer stem cells: lessons from leukemia
Wang, J. C. Y., & Dick, J. E. (2005) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.07.004 · Cited by 615
“This concept is supported by a correlation between genes required for normal hematopoietic development and those perturbed in leukemia [ 23 ] and by the recent demonstration that Bmi-1 is required for selfrenewal of both normal and leukemic HSCs in mice [24,25].”
BackgroundTranscription factors in myeloid development: balancing differentiation with transformation
Rosenbauer, F., & Tenen, D. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2024 · Cited by 606
“Furthermore, dysregulation of transcription factor activity has an important role in leukaemia, implicating these genes as potential targets for therapeutic intervention in myeloid and other cancer”
BackgroundSelf-citationEiring, A. M., Harb, J. G., Neviani, P., Garton, C., Oaks, J. J., Spizzo, R., Liu, S., Schwind, S., Santhanam, R., Hickey, C. J., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.007 · Cited by 560
“…region (UTR) of CEBPA mRNA, suppresses translation (Chang et al., 2007; Perrotti et al., 2002) of this master regulator of myeloid differentiation (Tenen, 2003). hnRNP E2 RNA-binding activity does not require posttranslational modifications, and its expression is transiently induced by cytokines…”
DNMT1-interacting RNAs block gene-specific DNA methylation
Di Ruscio, A., Ebralidze, A. K., Benoukraf, T., Amabile, G., Goff, L. A., Terragni, J., Figueroa, M. E., De Figueiredo Pontes, L. L., Alberich-Jorda, M., Zhang, P., et al. (2013) · Nature · doi:10.1038/nature12598 · Cited by 509
“To examine how transcription may regulate the levels of genomic methylation, we investigated methylation dynamics of the well-studied methylation-sensitive gene CEBPA 5–7 , including the potential involvement of noncoding (nc) RNAs originating within CEBPA locus.”
Self-citationZhang, P., Iwasaki-Arai, J., Iwasaki, H., Fenyus, M. L., Dayaram, T., Owens, B. M., Shigematsu, H., Levantini, E., Huettner, C. S., Lekstrom-Himes, J. A., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.11.006 · Cited by 504
Self-citationLigon, K. L., Huillard, E., Mehta, S., Kesari, S., Liu, H., Alberta, J. A., Bachoo, R. M., Kane, M., Louis, D. N., DePinho, R. A., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.009 · Cited by 501
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G. (2004) · Nature Genetics · doi:10.1038/ng1361 · Cited by 506
“, and of individuals with leukemia, in whom transcription factors are frequently downregulated or mutate”
BackgroundSelf-citationNF-κB addiction and its role in cancer: ‘one size does not fit all’
Chaturvedi, M. M., Sung, B., Yadav, V. R., Kannappan, R., & Aggarwal, B. B. (2011) · Oncogene · doi:10.1038/onc.2010.566 · Cited by 473
Cancer across the tree of life: cooperation and cheating in multicellularity
Aktipis, C. A., Boddy, A. M., Jansen, G., Hibner, U., Hochberg, M. E., Maley, C. C., & Wilkinson, G. S. (2015) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2014.0219 · Cited by 466
“I HC [2 39 ]o rm ito tic fig ur es in fix ed tis su es [2 40 ]) ca n re ve al pr ol ife rat ion”
BackgroundInfluentialFröhling, S., Schlenk, R. F., Stolze, I., Bihlmayr, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., & Döhner, K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.060 · Cited by 458
“(C/EBP ) is a transcription factor involved in the regulation of myelopoiesis [12-14].”
BackgroundJunB Deficiency Leads to a Myeloproliferative Disorder Arising from Hematopoietic Stem Cells
Passegué, E., Wagner, E. F., & Weissman, I. L. (2004) · Cell · doi:10.1016/j.cell.2004.10.010 · Cited by 440
“1 (Tenen, 2003) and to enforce self-renewal (Reya et al.”
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Myeloid Lineage Commitment from the Hematopoietic Stem Cell
Iwasaki, H., & Akashi, K. (2007) · Immunity · doi:10.1016/j.immuni.2007.06.004 · Cited by 394
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia
Kharas, M. G., Lengner, C. J., Al-Shahrour, F., Bullinger, L., Ball, B., Zaidi, S., Morgan, K., Tam, W., Paktinat, M., Okabe, R., et al. (2010) · Nature Medicine · doi:10.1038/nm.2187 · Cited by 379
Epigenetic Silencing of the Myelopoiesis Regulator microRNA-223 by the AML1/ETO Oncoprotein
Fazi, F., Racanicchi, S., Zardo, G., Starnes, L. M., Mancini, M., Travaglini, L., Diverio, D., Ammatuna, E., Cimino, G., Lo-Coco, F., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.09.020 · Cited by 382
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
Renneville, A., Roumier, C., Biggio, V, Nibourel, O., Boissel, N., Fenaux, P., & Preudhomme, C. (2008) · Leukemia · doi:10.1038/leu.2008.19 · Cited by 351
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
Fröhling, S., Scholl, C., Gilliland, D. G., & Levine, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.010 · Cited by 353
The Kruppel‐like factor KLF4 is a critical regulator of monocyte differentiation
Feinberg, M. W., Wara, A. K., Cao, Z., Lebedeva, M. A., Rosenbauer, F., Iwasaki, H., Hirai, H., Katz, J. P., Haspel, R. L., Gray, S., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601824 · Cited by 337
“Thus, stagespecific expression of various transcription factors helps dictate not only cell fate decisions in the myeloid lineage, but also the development of malignant transformation (Tenen, 2003; Rosenbauer et al, 2004).”
BackgroundSelf-citationDifferentiation therapy of leukemia: 3 decades of development.
Nowak, D., Stewart, D., & Koeffler, H. P. (2009) · Blood · doi:10.1182/blood-2009-01-198911 · Cited by 348
Glioma Stem Cells: A Midterm Exam
Stiles, C. D., & Rowitch, D. H. (2008) · Neuron · doi:10.1016/j.neuron.2008.05.031 · Cited by 330
Mutation of CEBPA in Familial Acute Myeloid Leukemia
Smith, M. L., Cavenagh, J. D., Lister, T. A., & Fitzgibbon, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041331 · Cited by 328
Abrogation of nuclear receptors Nr4a3 andNr4a1 leads to development of acute myeloid leukemia
Mullican, S. E., Zhang, S., Konopleva, M., Ruvolo, V., Andreeff, M., Milbrandt, J., & Conneely, O. M. (2007) · Nature Medicine · doi:10.1038/nm1579 · Cited by 324
“This leads to the accumulation of immature blasts at various stages of maturation and to the expansion of a transformed leukemic stem cell compartment arising either from HSCs or from downstream progenitors with self-renewal properties similar to those observed in normal HSCs (refs”
BackgroundMarcucci, G., Maharry, K., Radmacher, M. D., Mrózek, K., Vukosavljevic, T., Paschka, P., Whitman, S. P., Langer, C., Baldus, C. D., Liu, C.-G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5554 · Cited by 302
“Normal myeloid differentiation requires not only functional CEBPA, but also expression of RUNX1 and SPI1.(42) Recent studies reported that SPI1 is a major downstream target of RUNX1(48) and that GATA1 blocks SPI1-mediated gene transactivation.”
BackgroundMolecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors
Johnson, P. F. (2005) · Journal of Cell Science · doi:10.1242/jcs.02459 · Cited by 288
“Experiments showing that reinstating C/EBPα expression in AML cells suppresses their proliferation in vitro and tumorigenicity in vivo support these conclusions (Truong et al., 2003).”
BackgroundInfluentialC/EBPα mutations in acute myeloid leukaemias
Nerlov, C. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1363 · Cited by 280
Rosa, A., Ballarino, M., Sorrentino, A., Sthandier, O., De Angelis, F. G., Marchioni, M., Masella, B., Guarini, A., Fatica, A., Peschle, C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706963104 · Cited by 285
Landscape of TET2 mutations in acute myeloid leukemia
Weissmann, S., Alpermann, T., Grossmann, V, Kowarsch, A., Nadarajah, N., Eder, C., Dicker, F., Fasan, A., Haferlach, C., Haferlach, T., et al. (2012) · Leukemia · doi:10.1038/leu.2011.326 · Cited by 261
Oxidative stress, redox regulation and diseases of cellular differentiation
Ye, Z.-W., Zhang, J., Townsend, D. M., & Tew, K. D. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.11.010 · Cited by 257
“One of the most salient examples is acute myeloid leukemia (AML), an aggressive, age dependent hematopoietic malignancy characterized by an accumulation of granulocyte or monocyte precursors in the bone marrow and blood [72, 139].”
DETERMINANTS OF LYMPHOID-MYELOID LINEAGE DIVERSIFICATION
Laiosa, C. V., Stadtfeld, M., & Graf, T. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090742 · Cited by 259
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis.
Huang, G., Zhang, P., Hirai, H., Elf, S., Yan, X., Chen, Z., Koschmieder, S., Okuno, Y., Dayaram, T., Growney, J. D., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.7 · Cited by 259
“The complexity and importance of proper regulation in hematopoiesis is exemplified in human leukemia, which is often caused by chromosome translocations or mutations involving transcription factor”
BackgroundSelf-citationJendrzejewski, J., He, H., Radomska, H. S., Li, W., Tomsic, J., Liyanarachchi, S., Davuluri, R. V., Nagy, R., & de la Chapelle, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205654109 · Cited by 246
“C/EBPα is a major player in hematopoietic differentiation, and its involvement in hematologic malignancies is very well documented (37, 38).”
BackgroundTribbles homolog 2 inactivates C/EBPα and causes acute myelogenous leukemia
Keeshan, K., He, Y., Wouters, B. J., Shestova, O., Xu, L., Sai, H., Rodriguez, C. G., Maillard, I., Tobias, J. W., Valk, P., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.012 · Cited by 238
“Trib2 reduces normal C/EBPa levels and inhibits C/EBPa function A deficiency of the transcription factor C/EBPa inhibits granulocyte differentiation and is associated with AML (Tenen, 2003), features similar to the consequences of Trib2 expression in hematopoietic progenitors.”
BackgroundRisk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype
Bienz, M., Ludwig, M., Mueller, B. U., Oppliger Leibundgut, E., Ratschiller, D., Solenthaler, M., Fey, M. F., & Pabst, T. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1552 · Cited by 235
Zhang, H.-M., Kuang, S., Xiong, X., Gao, T., Liu, C., & Guo, A.-Y. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbt085 · Cited by 222
“Acute myeloid leukemia (AML) is characterized by the rapid growth of hematopoietic precursors blocked at different differentiation stages, such as erythroid, or granulocytic [74].”
BackgroundConcepts of human leukemic development
Warner, J. K., Wang, J. C. Y., Hope, K. J., Jin, L., & Dick, J. E. (2004) · Oncogene · doi:10.1038/sj.onc.1207933 · Cited by 225
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia
Ranganathan, P., Yu, X., Na, C., Santhanam, R., Shacham, S., Kauffman, M., Walker, A., Klisovic, R., Blum, W., Caligiuri, M., et al. (2012) · Blood · doi:10.1182/blood-2012-04-423160 · Cited by 220
Dysregulation of the C/EBPα Differentiation Pathway in Human Cancer
Koschmieder, S., Halmos, B., Levantini, E., & Tenen, D. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9812 · Cited by 212
“Recent studies demonstrate that C/EBP indeed acts as a bona fide tumor suppressor in a number of tumor types,(2,3) supporting the view that disruption of normal differentiation and its uncoupling from cell cycle arrest are key components in the development of cancer.(4) The present review will summarize our current un…”
BackgroundSelf-citationAkasaka, T., Balasas, T., Russell, L. J., Sugimoto, K.-J., Majid, A., Walewska, R., Karran, E. L., Brown, D. G., Cain, K., Harder, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-041012 · Cited by 215
“With the exception of CEBPD breakpoints, which were scattered within a 43-kb region centromeric of CEBPD, translocation breakpoints were clustered immediately 5 or 3 of the involved CEBP gene.”
BackgroundInfluentialMa, Y., Cui, W., Yang, J., Qu, J., Di, C., Amin, H. M., Lai, R., Ritz, J., Krause, D. S., & Chai, L. (2006) · Blood · doi:10.1182/blood-2006-02-001594 · Cited by 215
“SALL4A contained all exons (1-4) (Figure 1A), whereas SALL4B lacked a large portion of the 3 end of exon 2.”
BackgroundLin, L.-I., Chen, C.-Y., Lin, D.-T., Tsay, W., Tang, J.-L., Yeh, Y.-C., Shen, H.-L., Su, F.-H., Yao, M., Huang, S.-Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1816 · Cited by 214
“C/EBPa expression is selectively maintained during granulocyte differentiation but is markedly down-regulated with monocytic differentiation (3, 4).”
BackgroundChromatin structure and epigenetics
Quina, A. S., Buschbeck, M., & Di Croce, L. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.016 · Cited by 200
“This idea is supported by analysis of gene-knockout mice, which uncovered crucial roles of several transcription factors in normal hematopoiesis [50], and of individuals with leukemia, in whom transcription factors are frequently miss-expressed or mutated [51].”
ResultGlobal approach to the diagnosis of leukemia using gene expression profiling
Haferlach, T., Kohlmann, A., Schnittger, S., Dugas, M., Hiddemann, W., Kern, W., & Schoch, C. (2005) · Blood · doi:10.1182/blood-2004-12-4938 · Cited by 209
Höckendorf, U., Yabal, M., Herold, T., Munkhbaatar, E., Rott, S., Jilg, S., Kauschinger, J., Magnani, G., Reisinger, F., Heuser, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.002 · Cited by 199
“…that drive hematopoietic differentiation by paracrine/autocrin essentially demonstrating tumor-suppressive functions in A including FLT3-mutated patients, emphasizes the relevance of the pool of LIC, future concepts aiming at reinstating RIPK3 si and progenitor cells (HSPC) (Tenen, 2003).”
BackgroundInfluentialPabst, T., Eyholzer, M., Haefliger, S., Schardt, J., & Mueller, B. U. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5563 · Cited by 201
Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations
Radomska, H. S., Bassères, D. S., Zheng, R., Zhang, P., Dayaram, T., Yamamoto, Y., Sternberg, D. W., Lokker, N., Giese, N. A., Bohlander, S. K., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052242 · Cited by 199
Self-citationS100 protein family in human cancer.
Chen, H., Xu, C., Jin, Q., & Liu, Z. (2014) · Europe PMC (PubMed Central) · Cited by 276
Barreyro, L., Will, B., Bartholdy, B., Zhou, L., Todorova, T. I., Stanley, R. F., Ben-Neriah, S., Montagna, C., Parekh, S., Pellagatti, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404699 · Cited by 201
Riether, C., Schürch, C. M., Bührer, E. D., Hinterbrandner, M., Huguenin, A.-L., Hoepner, S., Zlobec, I., Pabst, T., Radpour, R., & Ochsenbein, A. F. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20152008 · Cited by 191
“, 2014) often oppose differentiation-inducing programs in AML blasts, leading to a block in terminal differentiation and senescence (Tenen, 2003).”
BackgroundGain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia
Zhang, S.-J., Ma, L.-Y., Huang, Q.-H., Li, G., Gu, B.-W., Gao, X.-D., Shi, J.-Y., Wang, Y.-Y., Gao, L., Cai, X., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711824105 · Cited by 181
“Additional genetic events have been reported to be associated with CML progression, including duplication of the Ph chromosome, trisomy 8, isochromosome i(17q), and mutations in tumor suppressor genes such as INK4A/ARF, p53, and Rb (5, 6).”
BackgroundCEBPA point mutations in hematological malignancies
Leroy, H., Roumier, C., Huyghe, P., Biggio, V, Fenaux, P., & Preudhomme, C. (2005) · Leukemia · doi:10.1038/sj.leu.2403614 · Cited by 190
The role of the GATA2 transcription factor in normal and malignant hematopoiesis
Vicente, C., Conchillo, A., García-Sánchez, M. A., & Odero, M. D. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.007 · Cited by 175
“Disruption of expression of transcription factors reguating proliferation, survival and differentiation of myeloid rogenitors is directly linked to acute myeloid leukemogeesis [161].”
BackgroundEssential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells
Steidl, U., Rosenbauer, F., Verhaak, R. G. W., Gu, X., Ebralidze, A., Otu, H. H., Klippel, S., Steidl, C., Bruns, I., Costa, D. B., et al. (2006) · Nature Genetics · doi:10.1038/ng1898 · Cited by 184
“This is particularly true for AML, in which a developmental block is a hallmark of the disease and results in a bulk tumor population of immature cells that cannot be easily compared with normal blood or bone marrow cell”
BackgroundSelf-citationEbralidze, A. K., Guibal, F. C., Steidl, U., Zhang, P., Lee, S., Bartholdy, B., Jorda, M. A., Petkova, V., Rosenbauer, F., Huang, G., et al. (2008) · Genes & Development · doi:10.1101/gad.1654808 · Cited by 176
“1988) that is absolutely required for normal hematopoiesis (Tenen 2003).”
BackgroundSelf-citationGao, X.-N., Lin, J., Li, Y.-H., Gao, L., Wang, X.-R., Wang, W., Kang, H.-Y., Yan, G.-T., Wang, L.-L., & Yu, L. (2011) · Oncogene · doi:10.1038/onc.2011.62 · Cited by 179
“Oncogene (2011) 30, 3416–3428 & 2011 Macmillan Publishers Limited All rights reserved 0950-9232/11 www.nature.com/onc Tumor-specific downregulation of subsets of miRNAs has been described in the initiation and progression of leukemia (Tenen, 2003; Marcucci et al., 2008; Garzon et al., 2009).”
BackgroundTerminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML
Sexauer, A., Perl, A., Yang, X., Borowitz, M., Gocke, C., Rajkhowa, T., Thiede, C., Frattini, M., Nybakken, G. E., Pratz, K., et al. (2012) · Blood · doi:10.1182/blood-2012-01-402545 · Cited by 179
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
Okoye-Okafor, U. C., Bartholdy, B., Cartier, J., Gao, E. N., Pietrak, B., Rendina, A. R., Rominger, C., Quinn, C., Smallwood, A., Wiggall, K. J., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1930 · Cited by 180
Cancer Stem Cell Immunology: Key to Understanding Tumorigenesis and Tumor Immune Escape?
Bruttel, V. S., & Wischhusen, J. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00360 · Cited by 174
“Oncogenic mutations may also increase the frequency of cell divisions in otherwise fairly quiescent stem cells (150) or inhibit differentiation in the respective daughter cells (151, 152).”
BackgroundPotential Autoregulation of Transcription Factor PU.1 by an Upstream Regulatory Element
Okuno, Y., Huang, G., Rosenbauer, F., Evans, E. K., Radomska, H. S., Iwasaki, H., Akashi, K., Moreau-Gachelin, F., Li, Y., Zhang, P., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.7.2832-2845.2005 · Cited by 174
“Autoregulation may be a common feature of several transcriptional regulators to augment the relatively irreversible nature of differentiation processes in the hematopoietic system (60, 61).”
BackgroundSelf-citationDiscovering chemical modifiers of oncogene-regulated hematopoietic differentiation
Yeh, J.-R. J., Munson, K. M., Elagib, K. E., Goldfarb, A. N., Sweetser, D. A., & Peterson, R. T. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.147 · Cited by 163
“Many oncogenes found in leukemia encode transcription factors that regulate hematopoietic differentiatio”
BackgroundSCL: From the origin of hematopoiesis to stem cells and leukemia
Lécuyer, É., & Hoang, T. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2003.10.010 · Cited by 193
“Many of the genes that encode crucial hematopoietic ranscription factors are also deregulated in human leukeias [8–11], strengthening the view that the appropriate egulation of transcription factor networks is pivotal for aintaining proper tissue homeostasis within the hematopoitic compartment.”
BackgroundWang, K., Wang, P., Shi, J., Zhu, X., He, M., Jia, X., Yang, X., Qiu, F., Jin, W., Qian, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.045 · Cited by 162
Childhood and Adolescent Lymphoid and Myeloid Leukemia
Pui, C.-H., Schrappe, M., Ribeiro, R. C., & Niemeyer, C. M. (2004) · Hematology · doi:10.1182/asheducation-2004.1.118 · Cited by 163
Kho, A. T., Zhao, Q., Cai, Z., Butte, A. J., Kim, J. Y. H., Pomeroy, S. L., Rowitch, D. H., & Kohane, I. S. (2004) · Genes & Development · doi:10.1101/gad.1182504 · Cited by 163
“For instance, in acute myelogenous leukemia, evidence exists for the disruption of normal hematopoietic differentiation programs (Reya et al. 2001; Tenen 2003).”
BackgroundMechanisms involved in the induced differentiation of leukemia cells
Tsiftsoglou, A. S., Pappas, I. S., & Vizirianakis, I. S. (2003) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.09.002 · Cited by 181
“Evidence exists to indicate that leukemias result from disruption of differentiation of hematopoietic cells (Bonnet & Dick, 1997; Enver & Greaves, 1998; Tenen, 2003).”
BackgroundBishop, R. (2010) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzq009 · Cited by 157
Cbfβ-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia
Kuo, Y., Landrette, S. F., Heilman, S. A., Perrat, P. N., Garrett, L. J., Liu, P. P., Beau, M. M. L., Kogan, S. C., & Castilla, L. H. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.014 · Cited by 159
“Myeloiderythroid differentiation is tightly regulated by transcription factors ( Tenen, 2003 ).”
BackgroundPhosphorylation of C/EBPα Inhibits Granulopoiesis
Ross, S. E., Radomska, H. S., Wu, B., Zhang, P., Winnay, J. N., Bajnok, L., Wright, W. S., Schaufele, F., Tenen, D. G., & MacDougald, O. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.2.675-686.2004 · Cited by 146
“Thus, multiple mechanisms that result in inhibition of C/EBP protein function contribute to myeloid leukemias ( 44 ).”
BackgroundSelf-citationRoeder, I., & Glauche, I. (2006) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2006.01.021 · Cited by 142
“…component network model is motivated by experimental observations on the transcription factors GATA-1 and PU.1, known to be involved in the process of lineage specification of HSC (Du et al., 2002; Oikawa et al., 1999; Rekhtman et al., 1999; Rosmarin et al., 2005; Tenen, 2003; Voso et al., 1994).”
BackgroundMethodInfluentialPalii, C. G., Perez-Iratxeta, C., Yao, Z., Cao, Y., Dai, F., Davison, J., Atkins, H., Allan, D., Dilworth, F. J., Gentleman, R., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.342 · Cited by 140
“type (Tenen, 2003; O’Neil and Look, 2007).”
Adult Hematopoietic Stem and Progenitor Cells Require Either Lyl1 or Scl for Survival
Souroullas, G. P., Salmon, J. M., Sablitzky, F., Curtis, D. J., & Goodell, M. A. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.01.001 · Cited by 139
“Critical in hematopoietic development and adult homeostasis are a number of transcription factors, many of which are dysre- gulated in human leukemias (Look, 1997; Murre, 2000; Rabbitts, 1994; Shivdasani and Orkin, 1996; Tenen, 2003).”
Cook, W. D., McCaw, B. J., Herring, C., John, D. L., Foote, S. J., Nutt, S. L., & Adams, J. M. (2004) · Blood · doi:10.1182/blood-2004-06-2234 · Cited by 140
MicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determination
Fazi, F., & Nervi, C. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn151 · Cited by 137
“1, which cooperatively regulate promoters or enhancers present on their specific target genes.(84) In mammalian cells, specific miRNAs whose expression varies during haematopoiesis have recently been identified.”
BackgroundSelenium Cytotoxicity in Cancer
Wallenberg, M., Misra, S., & Björnstedt, M. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12207 · Cited by 145
“Acute myeloid leukemia is characterized by an uncontrolled outgrowth of hematopoetic stem cells or progenitors, and is a collective name for several subtypes of AML, divided after the causative of the disease [196].”
BackgroundPulikkan, J. A., Peramangalam, P. S., Dengler, V., Ho, P. A., Preudhomme, C., Meshinchi, S., Christopeit, M., Nibourel, O., Müller-Tidow, C., Bohlander, S. K., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281600 · Cited by 126
Self-citationTargeting cell cycle regulators in hematologic malignancies
Aleem, E., & Arceci, R. J. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00016 · Cited by 120
“Pharmacological inhibitors of CDK4/6 have been developed and are currently being tested in clinical trials (Supplementary Table 3).”
BackgroundBali, P., George, P., Cohen, P., Tao, J., Guo, F., Sigua, C., Vishvanath, A., Scuto, A., Annavarapu, S., Fiskus, W., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0210 · Cited by 125
Origins of aberrant DNA methylation in acute myeloid leukemia
Schoofs, T., Berdel, W. E., & Müller‐Tidow, C. (2013) · Leukemia · doi:10.1038/leu.2013.242 · Cited by 138
A new genomic framework to categorize pediatric acute myeloid leukemia
Umeda, M., Ma, J., Westover, T., Ni, Y., Song, G., Maciaszek, J. L., Rusch, M., Rahbarinia, D., Foy, S. G., Huang, B. J., et al. (2024) · Nature Genetics · doi:10.1038/s41588-023-01640-3 · Cited by 136
“Acute myeloid leukemia (AML) is characterized by aberrant clonal expansion of hematopoietic progenitors with differentiation defects 1–3 .”
BackgroundRosmarin, A. G., Yang, Z., & Resendes, K. K. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.08.015 · Cited by 121
“More thana dozen transcription factors play important roles in regulating myeloid genes [3–6].”
BackgroundModeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice
Tsuzuki, S., Seto, M., Greaves, M. F., & Enver, T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402063101 · Cited by 131
Altucci, L., Rossin, A., Hirsch, O., Nebbioso, A., Vitoux, D., Wilhelm, E., Guidez, F., De Simone, M., Schiavone, E. M., Grimwade, D., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3569 · Cited by 114
“Recent studies have supported the concept that aberrant expression or mutation of lineage–specific transcription factors, or the formation of abnormal transcription factor hybrids due to chromosome translocation cause this heterogeneous disease and correlate with specific FAB subtypes (3).”
InfluentialAML1-ETO reprograms hematopoietic cell fate by downregulatingsclexpression
Yeh, J.-R. J., Munson, K. M., Chao, Y. L., Peterson, Q. P., MacRae, C. A., & Peterson, R. T. (2007) · Development · doi:10.1242/dev.008904 · Cited by 125
“It is thought that many leukemic oncogenes, including AML1-ETO, may contribute to the development of AML by affecting the specification and maturation of hematopoietic cells (Tenen, 2003).”
BackgroundThe tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML
Eyholzer, M., Schmid, S., Wilkens, L., Mueller, B. U., & Pabst, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605751 · Cited by 115
“Deregulation of either haematopoietic transcription factors or miRNAs is a common event in the molecular pathogenesis of human leukaemias (Tenen, 2003; Kluiver et al, 2006; Rosenbauer and Tenen, 2007; Fabbri et al, 2008).”
BackgroundComplexity of CEBPA Dysregulation in Human Acute Myeloid Leukemia
Pabst, T., & Mueller, B. U. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2941 · Cited by 114
Interleukin-3 receptor in acute leukemia
Testa, U., Riccioni, R., Diverio, D., Rossini, A., Coco, F. L., & Peschle, C. (2003) · Leukemia · doi:10.1038/sj.leu.2403224 · Cited by 131
Heath, V., Suh, H. C., Holman, M., Renn, K., Gooya, J. M., Parkin, S., Klarmann, K. D., Ortiz, M., Johnson, P., & Keller, J. (2004) · Blood · doi:10.1182/blood-2003-11-3963 · Cited by 114
Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells.
Torchia, E. C., Jaishankar, S., & Baker, S. J. (2003) · PubMed · Cited by 116
Steidl, U., Steidl, C., Ebralidze, A., Chapuy, B., Han, H.-J., Will, B., Rosenbauer, F., Becker, A., Wagner, K., Koschmieder, S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30525 · Cited by 114
Self-citationThe Biology of HDAC in Cancer: The Nuclear and Epigenetic Components
Hagelkrüys, A., Sawicka, A., Rennmayr, M., & Seiser, C. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-21631-2_2 · Cited by 118
“Acute myeloid leukemia (AML) features a block inmyeloid differentiation and is an excellent disease model to examine the regulation of differentiation and cancer progression (Tenen 2003).”
BackgroundHarnessing the immune system in acute myeloid leukaemia
Austin, R. J., Smyth, M. J., & Lane, S. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.020 · Cited by 120
“Aberrant activity of transcription factors that block differentiation of myeloid cells [43].”
Nilsson, L., Edén, P., Olsson, E., Månsson, R., Åstrand-Grundström, I., Strömbeck, B., Theilgaard-Mönch, K., Anderson, K., Hast, R., Hellström-Lindberg, E., et al. (2007) · Blood · doi:10.1182/blood-2007-03-079368 · Cited by 112
MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia
Byers, R. J., Currie, T., Tholouli, E., Rodig, S. J., & Kutok, J. L. (2011) · Blood · doi:10.1182/blood-2011-04-346767 · Cited by 113
“12 In normal human HSCs, MSI2 is up-regulated by HOXA9,14 of importance considering the initial discovery of MSI2 in patients with CML carrying the t(7;17)(p15;q23) translocation, which resulted in a MSl2/HOXA9 fusion gene.”
BackgroundIshikawa, Y., Gamo, K., Yabuki, M., Takagi, S., Toyoshima, K., Nakayama, K., Nakayama, A., Morimoto, M., Miyashita, H., Dairiki, R., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0471 · Cited by 117
“Mol Cancer Ther; 16(2) February 2017 Molecular Cancer Therapeutics 274”
BackgroundInfluentialFujimoto, T., Anderson, K., Jacobsen, S. E. W., Nishikawa, S.-I., & Nerlov, C. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601675 · Cited by 113
“…interferes with Runx1 function The genes encoding C/EBPa, PU.1 and Runx1 are all targets of mutation or translocation in acute myeloid leukemia (AML), and myeloid-specific promoters generally depend on combined binding sites for these factors for their activity (Zhang et al, 1996; Tenen, 2003).”
Background
Metadata
- Authors
- Tenen, D. G.
- Affiliations
- Harvard University (US)
- Corresponding author
- Tenen, Daniel G.
- ORCID
- Tenen, Daniel G.
- Venue
- Nature Reviews Cancer
- Published
- 2003-02
- Volume
- 3
- Issue
- 2
- Pages
- 89-101
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2050249118
- Cited by
- 612
- References
- 128
- Citations by year
- 2026: 7 · 2025: 20 · 2024: 16 · 2023: 15 · 2022: 6 · 2021: 23 · 2020: 20 · 2019: 16 · 2018: 17 · 2017: 22 · 2016: 20 · 2015: 18 · 2014: 25 · 2013: 33 · 2012: 27
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- acute myeloid leukemia, cell differentiation, transcription factors, lineage-specific transcription factors, hematopoietic differentiation, transcription factor mutations, solid tumors
- MeSH terms
- Cell Differentiation, Humans, Mutation, Neoplasms, Transcription Factors, Leukemia, Myeloid, Acute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.